These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 17692027)

  • 1. Molecular design and clinical development of VEGFR kinase inhibitors.
    Zhong H; Bowen JP
    Curr Top Med Chem; 2007; 7(14):1379-93. PubMed ID: 17692027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent advances in small molecule inhibitors of VEGFR and EGFR signaling pathways.
    Zhong H; Bowen JP
    Curr Top Med Chem; 2011; 11(12):1571-90. PubMed ID: 21510831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective VEGFR inhibitors for anticancer therapeutics in clinical use and clinical trials.
    Zhang C; Tan C; Ding H; Xin T; Jiang Y
    Curr Pharm Des; 2012; 18(20):2921-35. PubMed ID: 22571661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy.
    Takahashi S
    Biol Pharm Bull; 2011; 34(12):1785-8. PubMed ID: 22130231
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis.
    Melincovici CS; Boşca AB; Şuşman S; Mărginean M; Mihu C; Istrate M; Moldovan IM; Roman AL; Mihu CM
    Rom J Morphol Embryol; 2018; 59(2):455-467. PubMed ID: 30173249
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenic agents: an update on small molecule VEGFR inhibitors.
    Schenone S; Bondavalli F; Botta M
    Curr Med Chem; 2007; 14(23):2495-516. PubMed ID: 17979703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy.
    Underiner TL; Ruggeri B; Gingrich DE
    Curr Med Chem; 2004 Mar; 11(6):731-45. PubMed ID: 15032727
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
    Roodhart JM; Langenberg MH; Witteveen E; Voest EE
    Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recent advances in the development of dual VEGFR and c-Met small molecule inhibitors as anticancer drugs.
    Zhang J; Jiang X; Jiang Y; Guo M; Zhang S; Li J; He J; Liu J; Wang J; Ouyang L
    Eur J Med Chem; 2016 Jan; 108():495-504. PubMed ID: 26717201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of second-generation VEGFR tyrosine kinase inhibitors: current status.
    Bhargava P; Robinson MO
    Curr Oncol Rep; 2011 Apr; 13(2):103-11. PubMed ID: 21318618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF/VEGFR pathway inhibitors as anti-angiogenic agents: present and future.
    Sharma PS; Sharma R; Tyagi T
    Curr Cancer Drug Targets; 2011 Jun; 11(5):624-53. PubMed ID: 21486218
    [TBL] [Abstract][Full Text] [Related]  

  • 12. VEGFR-2 inhibitors and the therapeutic applications thereof: a patent review (2012-2016).
    Peng FW; Liu DK; Zhang QW; Xu YG; Shi L
    Expert Opin Ther Pat; 2017 Sep; 27(9):987-1004. PubMed ID: 28621580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of Raf kinase in cancer: therapeutic potential of targeting the Raf/MEK/ERK signal transduction pathway.
    Gollob JA; Wilhelm S; Carter C; Kelley SL
    Semin Oncol; 2006 Aug; 33(4):392-406. PubMed ID: 16890795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recent progress of small molecular VEGFR inhibitors as anticancer agents.
    Xu D; Wang TL; Sun LP; You QD
    Mini Rev Med Chem; 2011 Jan; 11(1):18-31. PubMed ID: 21034401
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
    Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
    Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
    Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
    Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AEE788: a dual family epidermal growth factor receptor/ErbB2 and vascular endothelial growth factor receptor tyrosine kinase inhibitor with antitumor and antiangiogenic activity.
    Traxler P; Allegrini PR; Brandt R; Brueggen J; Cozens R; Fabbro D; Grosios K; Lane HA; McSheehy P; Mestan J; Meyer T; Tang C; Wartmann M; Wood J; Caravatti G
    Cancer Res; 2004 Jul; 64(14):4931-41. PubMed ID: 15256466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [VEGF-receptor inhibitors for anti-angiogenesis].
    Shibuya M
    Nihon Yakurigaku Zasshi; 2003 Dec; 122(6):498-503. PubMed ID: 14639004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sunitinib inhibits catecholamine synthesis and secretion in pheochromocytoma tumor cells by blocking VEGF receptor 2 via PLC-γ-related pathways.
    Aita Y; Ishii KA; Saito Y; Ikeda T; Kawakami Y; Shimano H; Hara H; Takekoshi K
    Am J Physiol Endocrinol Metab; 2012 Oct; 303(8):E1006-14. PubMed ID: 22912364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quinazoline-based multi-tyrosine kinase inhibitors: synthesis, modeling, antitumor and antiangiogenic properties.
    Conconi MT; Marzaro G; Urbani L; Zanusso I; Di Liddo R; Castagliuolo I; Brun P; Tonus F; Ferrarese A; Guiotto A; Chilin A
    Eur J Med Chem; 2013 Sep; 67():373-83. PubMed ID: 23900004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.